FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207694822> ?p ?o ?g. }

• W3207694822 endingPage "S1097" @default.
• W3207694822 startingPage "S1097" @default.
• W3207694822 abstract "Telisotuzumab vedotin (Teliso-V) is an anti-c-Met antibody conjugated with a tubulin inhibitor, monomethylauristatin E. The c-Met receptor tyrosine kinase is the cell surface receptor for hepatocyte growth factor (HGF) encoded for by the MET proto-oncogene. c-Met overexpression occurs in various solid tumors, including non-small cell lung cancer (NSCLC), and the aberrant activation of the c-Met/HGF axis contributes to tumor progression, angiogenesis, invasive growth, metastasis, and resistance to therapies. Following encouraging evidence of anti-tumor activity in a Phase 1 study (Strickler et al. J Clin Oncol 2018;36:3298–3306), a Phase 2 study was initiated to explore the safety and efficacy of Teliso-V monotherapy in 3 cohorts (based on histopathology and epidermal growth factor receptor [EGFR] mutation) and 5 subgroups (based on c-Met expression) of patients with c-Met+ advanced NSCLC (study Stage 1), followed by expansion into an appropriately selected population based on study Stage 1 results for further evaluation of safety and efficacy (study Stage 2). This Phase 2, non-randomized, single-arm, adaptive study (NCT03539536) is enrolling patients aged ≥18 years with Eastern Cooperative Oncology Group performance status ≤1 and locally advanced or metastatic c-Met+ NSCLC who have received 1–2 prior lines of therapy (including systemic chemotherapy, immunotherapy, and targeted therapy, if eligible). Based on data from study Stage 1 (Camidge et al. AACR 2021), the cohort of patients with non-squamous EGFR wild type c-Met+ NSCLC met prespecified criteria to transition to the study Stage 2 single-arm expansion cohort. Study Stage 2 enrollment commenced in February 2021 and is ongoing; up to approximately 160 patients will be enrolled in study Stage 2. c-Met status is determined centrally by immunohistochemistry. The primary endpoint is overall response rate per independent central review (based on Response Evaluation Criteria in Solid Tumors version 1.1). Secondary endpoints are duration of response, disease control rate, progression-free survival, and overall survival. Quality of life will be evaluated as an exploratory efficacy endpoint and safety and tolerability will be assessed. Pharmacokinetic and biomarker samples will also be collected for analysis. Teliso-V is administered as a 30±10 min intravenous infusion at a dose of 1.9 mg/kg every 2 weeks until disease progression or study discontinuation criteria are met. ▪▪▪ ▪▪▪" @default.
• W3207694822 created "2021-10-25" @default.
• W3207694822 creator A5003172592 @default.
• W3207694822 creator A5004732154 @default.
• W3207694822 creator A5004928583 @default.
• W3207694822 creator A5007475481 @default.
• W3207694822 creator A5031362509 @default.
• W3207694822 creator A5036134937 @default.
• W3207694822 creator A5039075823 @default.
• W3207694822 creator A5042853916 @default.
• W3207694822 creator A5049406453 @default.
• W3207694822 creator A5058623156 @default.
• W3207694822 creator A5059093147 @default.
• W3207694822 creator A5059941445 @default.
• W3207694822 creator A5069589468 @default.
• W3207694822 creator A5082517668 @default.
• W3207694822 date "2021-10-01" @default.
• W3207694822 modified "2023-09-26" @default.
• W3207694822 title "P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2" @default.
• W3207694822 doi "https://doi.org/10.1016/j.jtho.2021.08.496" @default.
• W3207694822 hasPublicationYear "2021" @default.
• W3207694822 type Work @default.
• W3207694822 sameAs 3207694822 @default.
• W3207694822 citedByCount "1" @default.
• W3207694822 countsByYear W32076948222023 @default.
• W3207694822 crossrefType "journal-article" @default.
• W3207694822 hasAuthorship W3207694822A5003172592 @default.
• W3207694822 hasAuthorship W3207694822A5004732154 @default.
• W3207694822 hasAuthorship W3207694822A5004928583 @default.
• W3207694822 hasAuthorship W3207694822A5007475481 @default.
• W3207694822 hasAuthorship W3207694822A5031362509 @default.
• W3207694822 hasAuthorship W3207694822A5036134937 @default.
• W3207694822 hasAuthorship W3207694822A5039075823 @default.
• W3207694822 hasAuthorship W3207694822A5042853916 @default.
• W3207694822 hasAuthorship W3207694822A5049406453 @default.
• W3207694822 hasAuthorship W3207694822A5058623156 @default.
• W3207694822 hasAuthorship W3207694822A5059093147 @default.
• W3207694822 hasAuthorship W3207694822A5059941445 @default.
• W3207694822 hasAuthorship W3207694822A5069589468 @default.
• W3207694822 hasAuthorship W3207694822A5082517668 @default.
• W3207694822 hasBestOaLocation W32076948221 @default.
• W3207694822 hasConcept C121608353 @default.
• W3207694822 hasConcept C126322002 @default.
• W3207694822 hasConcept C143998085 @default.
• W3207694822 hasConcept C146357865 @default.
• W3207694822 hasConcept C151730666 @default.
• W3207694822 hasConcept C170493617 @default.
• W3207694822 hasConcept C2776256026 @default.
• W3207694822 hasConcept C2776996007 @default.
• W3207694822 hasConcept C2779013556 @default.
• W3207694822 hasConcept C2779438470 @default.
• W3207694822 hasConcept C2780467284 @default.
• W3207694822 hasConcept C2781230642 @default.
• W3207694822 hasConcept C2908647359 @default.
• W3207694822 hasConcept C71924100 @default.
• W3207694822 hasConcept C86803240 @default.
• W3207694822 hasConcept C99454951 @default.
• W3207694822 hasConceptScore W3207694822C121608353 @default.
• W3207694822 hasConceptScore W3207694822C126322002 @default.
• W3207694822 hasConceptScore W3207694822C143998085 @default.
• W3207694822 hasConceptScore W3207694822C146357865 @default.
• W3207694822 hasConceptScore W3207694822C151730666 @default.
• W3207694822 hasConceptScore W3207694822C170493617 @default.
• W3207694822 hasConceptScore W3207694822C2776256026 @default.
• W3207694822 hasConceptScore W3207694822C2776996007 @default.
• W3207694822 hasConceptScore W3207694822C2779013556 @default.
• W3207694822 hasConceptScore W3207694822C2779438470 @default.
• W3207694822 hasConceptScore W3207694822C2780467284 @default.
• W3207694822 hasConceptScore W3207694822C2781230642 @default.
• W3207694822 hasConceptScore W3207694822C2908647359 @default.
• W3207694822 hasConceptScore W3207694822C71924100 @default.
• W3207694822 hasConceptScore W3207694822C86803240 @default.
• W3207694822 hasConceptScore W3207694822C99454951 @default.
• W3207694822 hasIssue "10" @default.
• W3207694822 hasLocation W32076948221 @default.
• W3207694822 hasOpenAccess W3207694822 @default.
• W3207694822 hasPrimaryLocation W32076948221 @default.
• W3207694822 hasRelatedWork W1990393102 @default.
• W3207694822 hasRelatedWork W1990395674 @default.
• W3207694822 hasRelatedWork W2037082948 @default.
• W3207694822 hasRelatedWork W2060263774 @default.
• W3207694822 hasRelatedWork W2169921827 @default.
• W3207694822 hasRelatedWork W2370136380 @default.
• W3207694822 hasRelatedWork W2417693965 @default.
• W3207694822 hasRelatedWork W3032385392 @default.
• W3207694822 hasRelatedWork W4311247368 @default.
• W3207694822 hasRelatedWork W2597201175 @default.
• W3207694822 hasVolume "16" @default.
• W3207694822 isParatext "false" @default.
• W3207694822 isRetracted "false" @default.
• W3207694822 magId "3207694822" @default.
• W3207694822 workType "article" @default.